A development-stage biotechnology company focused on oncology therapies derived from small molecules, including investigational treatments targeting melanoma and other cancers. Its lead candidate, PV-10, has been studied for intralesional treatment of solid tumors, with value tied largely to clinica...
1 member of Congress has disclosed 1 trade in Provectus Biopharm. (PVCT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-21 | CHARLES J. "CHUCK" FLEISCHMANN | buy | $1K – $15K |